KALVISTA PHARMACEUTICALS ($KALV) is expected to release its quarterly earnings data on Thursday, September 4th after market close, per Finnhub. Analysts are expecting revenue of $2,130,525 and earnings of -$0.97 per share.
You can see Quiver Quantitative's $KALV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KALVISTA PHARMACEUTICALS Insider Trading Activity
KALVISTA PHARMACEUTICALS insiders have traded $KALV stock on the open market 23 times in the past 6 months. Of those trades, 1 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $KALV stock by insiders over the last 6 months:
- BENJAMIN L PALLEIKO (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 7 sales selling 75,973 shares for an estimated $1,067,940.
- CHRISTOPHER YEA (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 7 sales selling 44,058 shares for an estimated $647,173.
- HEALTHCARE CAPITAL PARTNERS III, L.P. VENROCK purchased 25,000 shares for an estimated $235,500
- PAUL K. AUDHYA (CHIEF MEDICAL OFFICER) has made 0 purchases and 6 sales selling 15,828 shares for an estimated $198,087.
- NICOLE SWEENY (Chief Commercial Officer) has made 0 purchases and 2 sales selling 3,344 shares for an estimated $44,508.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KALVISTA PHARMACEUTICALS Hedge Fund Activity
We have seen 85 institutional investors add shares of KALVISTA PHARMACEUTICALS stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC added 905,053 shares (+2258.6%) to their portfolio in Q2 2025, for an estimated $10,231,624
- GREAT POINT PARTNERS LLC removed 691,197 shares (-68.1%) from their portfolio in Q2 2025, for an estimated $7,813,982
- DIMENSIONAL FUND ADVISORS LP removed 472,784 shares (-73.2%) from their portfolio in Q2 2025, for an estimated $5,344,823
- SCHONFELD STRATEGIC ADVISORS LLC removed 436,464 shares (-75.0%) from their portfolio in Q2 2025, for an estimated $4,934,225
- ALLOSTERY INVESTMENTS LP removed 418,302 shares (-91.3%) from their portfolio in Q2 2025, for an estimated $4,728,904
- JPMORGAN CHASE & CO removed 379,286 shares (-94.2%) from their portfolio in Q2 2025, for an estimated $4,287,828
- JEFFERIES FINANCIAL GROUP INC. removed 375,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,239,375
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
KALVISTA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $KALV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/11/2025
- Needham issued a "Buy" rating on 04/08/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/26/2025
- Jones Trading issued a "Buy" rating on 03/26/2025
To track analyst ratings and price targets for KALVISTA PHARMACEUTICALS, check out Quiver Quantitative's $KALV forecast page.
KALVISTA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $KALV recently. We have seen 6 analysts offer price targets for $KALV in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Andrew Fein from HC Wainwright & Co. set a target price of $27.0 on 07/11/2025
- Jonathan Wolleben from JMP Securities set a target price of $27.0 on 07/08/2025
- Joseph Schwartz from Leerink Partners set a target price of $20.0 on 07/07/2025
- Serge Belanger from Needham set a target price of $28.0 on 04/08/2025
- Jonathan Wolleben from Citizens Capital Markets set a target price of $19.0 on 03/26/2025
- Debanjana Chatterjee from Jones Trading set a target price of $30.0 on 03/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
